Part D Coverage Gap Discounts Not Linked To Price Increases In 2011 – GAO
This article was originally published in The Pink Sheet Daily
Executive Summary
GAO found the prices for high-expenditure brand-name drugs used by beneficiaries in the Medicare Part D coverage gap and by those who did not reach the gap in 2011 increased at a similar rate before and after the discount program was implemented in January 2011.
You may also be interested in...
Part D Premiums Will Increase If Manufacturers Offset Donut Hole Drug Discounts With Lower Rebates, Humana Warns
Medicare Part D beneficiary premiums will increase if drug firms try to offset new 50 percent discounts on branded drugs provided to beneficiaries in the coverage gap by reducing or eliminating the rebates paid to plans, Humana VP-Pharmacy and Clinical Integration William Fleming warned at a June 1 CMS workshop
CMS Expects Part D Rebates Will Continue Despite Donut Hole Discounts, Guidance Says
CMS addresses stakeholder concerns in final guidance on Part D donut hole discount program.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.